US equities |
MU $934.27 ▲+0.00% INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% NVDA $213.66 ▲+0.00% AMZN $243.79 ▲+0.00% AAPL $348.91 ▲+0.00% SKHY $162.09 ▲+0.00% AMD $566.42 ▲+0.00%
FinancialContent

Nautilus Biotechnology, Inc. - Common Stock (NQ:NAUT)

3.140 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nautilus Biotechnology, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit Presentations Now Available On Demand
Via ACCESS Newswire
News headline image
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
Via ACCESS Newswire
News headline image
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
News headline image
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >